Equillium, Inc. (NASDAQ:EQ) Short Interest Update

Equillium, Inc. (NASDAQ:EQGet Rating) saw a significant increase in short interest in March. As of March 31st, there was short interest totalling 865,300 shares, an increase of 33.3% from the March 15th total of 648,900 shares. Based on an average daily trading volume, of 50,600 shares, the days-to-cover ratio is presently 17.1 days. Approximately 4.7% of the shares of the stock are short sold.

EQ has been the subject of a number of research reports. Zacks Investment Research lowered Equillium from a “buy” rating to a “hold” rating in a research report on Wednesday, March 30th. HC Wainwright lifted their price objective on Equillium from $12.00 to $15.00 and gave the stock a “buy” rating in a research report on Thursday, March 24th. Stifel Nicolaus reiterated a “buy” rating and issued a $12.00 price objective on shares of Equillium in a research report on Friday, March 25th. Finally, SVB Leerink lowered their price objective on Equillium from $18.00 to $14.00 and set an “outperform” rating for the company in a research report on Wednesday, January 5th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, Equillium presently has a consensus rating of “Buy” and an average target price of $11.75.

In other news, CFO Jason A. Keyes sold 8,000 shares of the firm’s stock in a transaction on Monday, April 4th. The stock was sold at an average price of $3.18, for a total value of $25,440.00. Following the completion of the sale, the chief financial officer now directly owns 23,296 shares in the company, valued at $74,081.28. The sale was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 32.70% of the company’s stock.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Dimensional Fund Advisors LP acquired a new stake in Equillium during the 4th quarter valued at $38,000. Citadel Advisors LLC acquired a new stake in Equillium during the 3rd quarter valued at $74,000. Two Sigma Securities LLC acquired a new stake in Equillium during the 3rd quarter valued at $573,000. Geode Capital Management LLC lifted its holdings in Equillium by 2.4% during the 3rd quarter. Geode Capital Management LLC now owns 154,185 shares of the company’s stock valued at $1,051,000 after purchasing an additional 3,603 shares during the last quarter. Finally, Victory Capital Management Inc. lifted its holdings in Equillium by 9.4% during the 3rd quarter. Victory Capital Management Inc. now owns 3,170,199 shares of the company’s stock valued at $21,621,000 after purchasing an additional 273,324 shares during the last quarter. 28.16% of the stock is owned by institutional investors.

Shares of Equillium stock traded up $0.03 during trading on Tuesday, hitting $3.10. 113 shares of the company were exchanged, compared to its average volume of 52,533. The company has a debt-to-equity ratio of 0.13, a current ratio of 9.35 and a quick ratio of 9.35. The firm’s fifty day moving average price is $3.44 and its 200 day moving average price is $4.40. Equillium has a 1-year low of $2.85 and a 1-year high of $7.75. The firm has a market capitalization of $106.26 million, a P/E ratio of -2.30 and a beta of 1.22.

Equillium (NASDAQ:EQGet Rating) last released its quarterly earnings data on Wednesday, March 23rd. The company reported ($0.36) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.01). As a group, equities research analysts anticipate that Equillium will post -1.4 earnings per share for the current year.

Equillium Company Profile (Get Rating)

Equillium, Inc, a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. Its primary product candidate is itolizumab, a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase 1b/2 clinical trials for the treatment of acute graft-versus-host disease; and Phase 1 clinical trial for the treatment of asthma and lupus nephritis.

Featured Stories

Receive News & Ratings for Equillium Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Equillium and related companies with MarketBeat.com's FREE daily email newsletter.